早期免疫表型指导的免疫调节策略与脓毒性休克重症监护结局:一项单中心回顾性队列研究
本研究为单中心回顾性观察性队列,纳入成人脓毒性休克患者1216例,在休克发生后1小时内基于常规生物标志物进行免疫表型分型,按预设24小时界标设计回顾性分为血液吸附组、IgM富集静脉免疫球蛋白(IVIG)组和标准治疗组。主要终点为第28天无升压药天数,血液吸附组最高、IgM富集IVIG组次之、标准治疗组最低;血液吸附与更快乳酸清除相关,IgM富集IVIG与第5天序贯器官衰竭评估评分改善更大相关;28天死亡率组间不同,血液吸附组最低。作者结论为关联性、假设生成性,支持进一步前瞻性表型分层研究。
要点
- 在1216例存活超过24小时的脓毒性休克患者中,第28天无升压药天数以血液吸附组最高、IgM富集IVIG组次之、标准治疗组最低。
- 血液吸附与更快的乳酸清除相关,IgM富集IVIG与第5天序贯器官衰竭评估评分改善更大相关。
- 28天死亡率组间不同,血液吸附组观察到的死亡率最低。
- 免疫表型分型在休克发生后1小时内基于常规可及生物标志物作为标准临床诊疗的一部分完成,按预设24小时界标设计回顾性分组。
- 作者认为这些发现为关联性、假设生成性,支持进一步在前瞻性表型分层研究中验证。
适用人群与场景
- 成人脓毒性休克患者,且存活超过第一个24小时(24小时界标队列)。
诊断标准与关键阈值
- 免疫表型分型:在休克发生后1小时内、基于常规可及生物标志物、作为标准临床诊疗的一部分完成。
- 分组:采用预设的24小时界标设计,按早期是否接受血液吸附、IgM富集静脉免疫球蛋白(IVIG)或标准治疗回顾性分类。
处置流程与药物剂量
- 早期免疫表型指导的免疫调节策略包括血液吸附、IgM富集静脉免疫球蛋白(IVIG)或标准治疗,按24小时界标回顾性分组比较。
研究设计与关键结果
- 研究类型:单中心回顾性观察性队列研究,样本量1216例成人脓毒性休克患者(24小时界标队列)。
- 主要终点:第28天无升压药天数,血液吸附组最高,IgM富集IVIG组次之,标准治疗组最低。
- 关键次要终点:血液吸附与更快乳酸清除相关;IgM富集IVIG与第5天序贯器官衰竭评估评分改善更大相关;28天死亡率组间不同,血液吸附组最低。
- 统计分析:采用倾向评分加权分析校正与常规临床实践相关的基线特征差异。
证据类型、等级与局限
- 证据类型:单中心回顾性观察性队列研究。
- 作者结论:这些发现应被解读为关联性和假设生成性,支持进一步在前瞻性表型分层研究中验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为早期免疫表型指导的免疫调节策略与不同的血流动力学稳定和器官恢复模式相关,这些发现为关联性、假设生成性,支持进一步前瞻性表型分层研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Septic shock is characterized by profound immune dysregulation, with marked heterogeneity in host inflammatory and immunosuppressive responses. This biological variability may contribute to the inconsistent effects observed in prior immunomodulatory interventions. Whether early immune phenotype-guided immunomodulation is associated with differential patterns of shock resolution and organ recovery remains incompletely understood.
METHODS: We conducted a single-center retrospective observational cohort study of adult patients with septic shock. Immune phenotyping using routinely available biomarkers was performed as part of standard clinical care within the first hour after shock onset. Using a prespecified 24-hour landmark design, patients were retrospectively classified according to early treatment with hemoadsorption, IgM-enriched intravenous immunoglobulin (IVIG), or standard care. The primary outcome was vasopressor-free days through day 28. Secondary outcomes included 28-day mortality, lactate kinetics, ventilator-free days, and changes in Sequential Organ Failure Assessment score. Propensity score-weighted analyses were applied to adjust for baseline differences in patient characteristics associated with routine clinical practice.
RESULTS: Among 1,216 patients included in the landmark cohort, vasopressor-free days through day 28 were highest in patients treated with hemoadsorption, followed by those receiving IgM-enriched IVIG, and lowest in the standard care group. Hemoadsorption was associated with faster lactate clearance, whereas IgM-enriched IVIG was associated with greater improvement in Sequential Organ Failure Assessment score by day 5. Twenty-eight-day mortality differed across groups, with the lowest mortality observed in the hemoadsorption group.
CONCLUSIONS: Among patients with septic shock who survived beyond the first 24 hours, early immune phenotype-guided immunomodulatory strategies applied during routine care were associated with distinct patterns of hemodynamic stabilization and organ recovery. These findings should be interpreted as associative and hypothesis-generating and support further investigation in prospective phenotype-stratified studies.
参考来源
- Aydogan MS, Saricicek V. Early Immune Phenotype-Guided Immunomodulatory Strategies and Intensive Care Outcomes in Septic Shock: A Single-Center Retrospective Cohort Study. Shock. 2026. PMID: 41949586. doi:10.1097/SHK.0000000000002813
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。